Furthermore, CD276 inhibits cancer cell responses to doxorubicin (DOX) via the AKT/TM4SF1/SIRT1 pathway, while knocking down B7-H3 promotes cell senescence upon DOX treatment [100]. This evidence concerns the gene CD276 and cancer.